hydroxychloroquine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 5 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient with chronic myelogenous leukemia who developed arthritis secondary to IFN therapy is presented." | 2.40 | Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention. ( Nesher, G; Ruchlemer, R, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horne, GA | 1 |
| Stobo, J | 1 |
| Kelly, C | 1 |
| Mukhopadhyay, A | 2 |
| Latif, AL | 1 |
| Dixon-Hughes, J | 1 |
| McMahon, L | 1 |
| Cony-Makhoul, P | 1 |
| Byrne, J | 1 |
| Smith, G | 1 |
| Koschmieder, S | 1 |
| BrÜmmendorf, TH | 1 |
| Schafhausen, P | 1 |
| Gallipoli, P | 1 |
| Thomson, F | 1 |
| Cong, W | 1 |
| Clark, RE | 1 |
| Milojkovic, D | 1 |
| Helgason, GV | 2 |
| Foroni, L | 1 |
| Nicolini, FE | 1 |
| Holyoake, TL | 2 |
| Copland, M | 1 |
| Eşkazan, AE | 1 |
| Han, B | 1 |
| Zhao, Y | 1 |
| Lin, Y | 1 |
| Fu, S | 1 |
| Wang, L | 1 |
| Zhang, M | 1 |
| Tie, R | 1 |
| Wang, B | 1 |
| Luo, Y | 1 |
| Liu, L | 1 |
| Yu, J | 1 |
| Huang, H | 1 |
| Karvela, M | 1 |
| Nesher, G | 1 |
| Ruchlemer, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Antineop | 1998 |
1 trial available for hydroxychloroquine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Female; Follow-Up Studie | 2020 |
3 other studies available for hydroxychloroquine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
Topics: Cytogenetic Analysis; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, | 2020 |
Hydroxychloroquine sensitizes chronic myeloid leukemia cells to Vγ9Vδ2 T cell-mediated lysis independent of autophagy.
Topics: Autophagy; Autophagy-Related Protein 7; Carrier Proteins; Cell Membrane; Cytoplasm; Drug Resistance, | 2017 |
Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase II as Topic; Fema | 2011 |